Targeting a neoantigen derived from a common TP53 mutation.
Targeting a neoantigen derived from a common TP53 mutation.
复制标题
DOI:
10.1126/science.abc8697
复制
发表时间:
2021-03-05
期刊:
影响因子:
--
通讯作者:
Zhou S
中科院分区:
文献类型:
--
作者:
Hsiue EH;Wright KM;Douglass J;Hwang MS;Mog BJ;Pearlman AH;Paul S;DiNapoli SR;Konig MF;Wang Q;Schaefer A;Miller MS;Skora AD;Azurmendi PA;Murphy MB;Liu Q;Watson E;Li Y;Pardoll DM;Bettegowda C;Papadopoulos N;Kinzler KW;Vogelstein B;Gabelli SB;Zhou S
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at position 175 is replaced with histidine) in complex with a common human leukocyte antigen–A (HLA-A) allele on the cell surface. We describe the structural basis of this specificity and its conversion into an immunotherapeutic agent: a bispecific single-chain diabody. Despite the extremely low p53 peptide-HLA complex density on the cancer cell surface, the bispecific antibody effectively activated T cells to lyse cancer cells that presented the neoantigen in vitro and in mice. This approach could in theory be used to target cancers containing mutations that are difficult to target in conventional ways.
登录
查看更多内容
DOI:
10.1056/nejmp1607591
发表时间:
2016-09-22
期刊:
The New England journal of medicine
影响因子:
--
作者:
Grossman RL;Heath AP;Ferretti V;Varmus HE;Lowy DR;Kibbe WA;Staudt LM
通讯作者:
Staudt LM
影响因子:
10.1
作者:
Gejman, Ron S.;Jones, Heather F.;Scheinberg, David A.
通讯作者:
Scheinberg, David A.
影响因子:
7.2
作者:
Cheng M;Santich BH;Xu H;Ahmed M;Huse M;Cheung NK
通讯作者:
Cheung NK
影响因子:
5.4
作者:
BEVERLEY, PCL;CALLARD, RE
通讯作者:
CALLARD, RE
影响因子:
5.8
作者:
Andreatta, Massimo;Nielsen, Morten
通讯作者:
Nielsen, Morten